BACKGROUND: Pre-clinical models demonstrate that platelet activation is involved in the spread of malignancy. Ongoing clinical trials are assessing whether aspirin, which inhibits platelet activation, can prevent or delay metastases.METHODS: Urinary 11-dehydro-thromboxane B2 (U-TXM), a biomarker of in vivo platelet activation, was measured after radical cancer therapy and correlated with patient demographics, tumour type, recent treatment, and aspirin use (100 mg, 300 mg or placebo daily) using multivariable linear regression models with log-transformed values.RESULTS: In total, 716 patients (breast 260, colorectal 192, gastro-oesophageal 53, prostate 211) median age 61 years, 50% male were studied. Baseline median U-TXM were breast 782; colorectal 1060; gastro-oesophageal 1675 and prostate 826 pg/mg creatinine; higher than healthy individuals (similar to 500 pg/mg creatinine). Higher levels were associated with raised body mass index, inflammatory markers, and in the colorectal and gastro-oesophageal participants compared to breast participants (P < 0.001) independent of other baseline characteristics. Aspirin 100 mg daily decreased U-TXM similarly across all tumour types (median reductions: 77-82%). Aspirin 300 mg daily provided no additional suppression of U-TXM compared with 100 mg.CONCLUSIONS: Persistently increased thromboxane biosynthesis was detected after radical cancer therapy, particularly in colorectal and gastro-oesophageal patients. Thromboxane biosynthesis should be explored further as a biomarker of active malignancy and may identify patients likely to benefit from aspirin.

Joharatnam-Hogan, N., Hatem, D., Cafferty, F. H., Petrucci, G., Cameron, D. A., Ring, A., Kynaston, H. G., Gilbert, D. C., Wilson, R. H., Hubner, R. A., Swinson, D. E. B., Cleary, S., Robbins, A., Mackenzie, M., Scott-Brown, M. W. G., Sothi, S., Dawson, L. K., Capaldi, L. M., Churn, M., Cunningham, D., Khoo, V., Armstrong, A. C., Ainsworth, N. L., Horan, G., Wheatley, D. A., Mullen, R., Lofts, F. J., Walther, A., Herbertson, R. A., Eaton, J. D., O'Callaghan, A., Eichholz, A., Kagzi, M. M., Patterson, D. M., Narahari, K., Bradbury, J., Stokes, Z., Rizvi, A. J., Walker, G. A., Kunene, V. L., Srihari, N., Gentry-Maharaj, A., Meade, A., Patrono, C., Rocca, B., Langley, R. E., Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial, <<BRITISH JOURNAL OF CANCER>>, 2023; 129 (4): 706-720. [doi:10.1038/s41416-023-02310-1] [https://hdl.handle.net/10807/271237]

Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial

Petrucci, Giovanna;Patrono, Carlo;Rocca, Bianca
Penultimo
Writing – Original Draft Preparation
;
2023

Abstract

BACKGROUND: Pre-clinical models demonstrate that platelet activation is involved in the spread of malignancy. Ongoing clinical trials are assessing whether aspirin, which inhibits platelet activation, can prevent or delay metastases.METHODS: Urinary 11-dehydro-thromboxane B2 (U-TXM), a biomarker of in vivo platelet activation, was measured after radical cancer therapy and correlated with patient demographics, tumour type, recent treatment, and aspirin use (100 mg, 300 mg or placebo daily) using multivariable linear regression models with log-transformed values.RESULTS: In total, 716 patients (breast 260, colorectal 192, gastro-oesophageal 53, prostate 211) median age 61 years, 50% male were studied. Baseline median U-TXM were breast 782; colorectal 1060; gastro-oesophageal 1675 and prostate 826 pg/mg creatinine; higher than healthy individuals (similar to 500 pg/mg creatinine). Higher levels were associated with raised body mass index, inflammatory markers, and in the colorectal and gastro-oesophageal participants compared to breast participants (P < 0.001) independent of other baseline characteristics. Aspirin 100 mg daily decreased U-TXM similarly across all tumour types (median reductions: 77-82%). Aspirin 300 mg daily provided no additional suppression of U-TXM compared with 100 mg.CONCLUSIONS: Persistently increased thromboxane biosynthesis was detected after radical cancer therapy, particularly in colorectal and gastro-oesophageal patients. Thromboxane biosynthesis should be explored further as a biomarker of active malignancy and may identify patients likely to benefit from aspirin.
2023
Inglese
Joharatnam-Hogan, N., Hatem, D., Cafferty, F. H., Petrucci, G., Cameron, D. A., Ring, A., Kynaston, H. G., Gilbert, D. C., Wilson, R. H., Hubner, R. A., Swinson, D. E. B., Cleary, S., Robbins, A., Mackenzie, M., Scott-Brown, M. W. G., Sothi, S., Dawson, L. K., Capaldi, L. M., Churn, M., Cunningham, D., Khoo, V., Armstrong, A. C., Ainsworth, N. L., Horan, G., Wheatley, D. A., Mullen, R., Lofts, F. J., Walther, A., Herbertson, R. A., Eaton, J. D., O'Callaghan, A., Eichholz, A., Kagzi, M. M., Patterson, D. M., Narahari, K., Bradbury, J., Stokes, Z., Rizvi, A. J., Walker, G. A., Kunene, V. L., Srihari, N., Gentry-Maharaj, A., Meade, A., Patrono, C., Rocca, B., Langley, R. E., Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial, <<BRITISH JOURNAL OF CANCER>>, 2023; 129 (4): 706-720. [doi:10.1038/s41416-023-02310-1] [https://hdl.handle.net/10807/271237]
File in questo prodotto:
File Dimensione Formato  
BJC july 2023.pdf

accesso aperto

Licenza: Creative commons
Dimensione 1.52 MB
Formato Adobe PDF
1.52 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/271237
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 10
social impact